Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) has provided an update.
Shandong Boan Biotechnology has announced that its controlling shareholder, Luye Pharma Group, plans to complete a previously announced transfer of H shares in the company through an additional on-market transaction. On 27 January 2026, Luye Pharma’s wholly owned subsidiary Shandong Luye Pharmaceutical will transfer 11,986,600 H shares to the issuer under the terms of a subscription agreement related to exchangeable preference shares, and the board does not expect the share transfer to have any material adverse impact on the group’s business operations.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong, focused on the research, development and commercialisation of innovative and biosimilar drugs, operating as part of the broader Luye Pharma Group healthcare ecosystem.
Average Trading Volume: 5,924,594
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.47B
See more data about 6955 stock on TipRanks’ Stock Analysis page.